MCID: BRN148
MIFTS: 23

Bronchial Benign Neoplasm

Categories: Cancer diseases, Respiratory diseases

Aliases & Classifications for Bronchial Benign Neoplasm

MalaCards integrated aliases for Bronchial Benign Neoplasm:

Name: Bronchial Benign Neoplasm 12
Benign Bronchial Neoplasm 15
Neoplasm of Bronchus 12
Bronchial Neoplasms 43
Bronchial Neoplasm 17
Bronchus Neoplasm 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3906
MeSH 43 D001984
SNOMED-CT 67 126705004
UMLS 71 C0006264

Summaries for Bronchial Benign Neoplasm

MalaCards based summary : Bronchial Benign Neoplasm, also known as benign bronchial neoplasm, is related to lung benign neoplasm and bronchus cancer. An important gene associated with Bronchial Benign Neoplasm is ZCCHC9 (Zinc Finger CCHC-Type Containing 9). The drugs Vinorelbine and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include lung, thyroid and breast.

Related Diseases for Bronchial Benign Neoplasm

Diseases related to Bronchial Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Related Disease Score Top Affiliating Genes
1 lung benign neoplasm 29.3 SFTPC SCGB1A1 NKX2-1
2 bronchus cancer 11.9
3 pulmonary blastoma 10.6
4 pleuropulmonary blastoma type 1 10.6
5 pleuropulmonary blastoma type 2 10.6
6 pleuropulmonary blastoma type 3 10.6
7 pleuropulmonary blastoma 10.5
8 well-differentiated fetal adenocarcinoma of the lung 10.5
9 lung cancer 10.5
10 small cell cancer of the lung 10.2
11 main bronchus cancer 10.2
12 respiratory distress syndrome in premature infants 10.0 SFTPC NKX2-1
13 lung carcinoma in situ 10.0 SFTPC NKX2-1
14 pulmonary adenocarcinoma in situ 10.0 SFTPC NKX2-1
15 peritoneal serous adenocarcinoma 9.9 SFTPC NKX2-1
16 mycobacterium tuberculosis 1 9.9
17 squamous cell papilloma 9.9
18 papilloma 9.9
19 bronchitis 9.9
20 actinomycosis 9.9
21 adenoma 9.9
22 neonatal respiratory failure 9.8 SFTPC SCGB1A1 NKX2-1
23 respiratory failure 9.8 SFTPC SCGB1A1 NKX2-1
24 papillary adenoma 9.8 SFTPC SCGB1A1 NKX2-1
25 subleukemic leukemia 9.8 SFTPC SCGB1A1
26 diaphragm disease 9.8 SFTPC NKX2-1
27 newborn respiratory distress syndrome 9.8 SFTPC SCGB1A1 NKX2-1
28 alcohol dependence 9.8
29 pneumothorax, primary spontaneous 9.8
30 sarcoidosis 1 9.8
31 congenital heart defects, hamartomas of tongue, and polysyndactyly 9.8
32 kearns-sayre syndrome 9.8
33 adenoid cystic carcinoma 9.8
34 bronchial disease 9.8
35 bronchopneumonia 9.8
36 megaesophagus 9.8
37 pleuropneumonia 9.8
38 candidiasis 9.8
39 pneumothorax 9.8
40 pulmonary tuberculosis 9.8
41 plasmacytoma 9.8
42 mucoepidermoid carcinoma 9.8
43 peritonitis 9.8
44 extrinsic allergic alveolitis 9.8
45 bullous pemphigoid 9.8
46 achalasia 9.8
47 hypereosinophilic syndrome 9.8
48 hemangioendothelioma 9.8
49 bronchiolo-alveolar adenocarcinoma 9.7 NKX2-1 MIR32 MIR30C1
50 lung adenoma 9.6 SFTPC SCGB1A1 MIR30C1

Graphical network of the top 20 diseases related to Bronchial Benign Neoplasm:



Diseases related to Bronchial Benign Neoplasm

Symptoms & Phenotypes for Bronchial Benign Neoplasm

Drugs & Therapeutics for Bronchial Benign Neoplasm

Drugs for Bronchial Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 55)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
2
Gemcitabine Approved Phase 3 95058-81-4 60750
3
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
4
Pemetrexed Approved, Investigational Phase 3 137281-23-3, 150399-23-8 60843 446556
5
leucovorin Approved Phase 3 58-05-9 6006 143
6
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
7
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
8
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
9 Immunologic Factors Phase 3
10 Anti-Infective Agents Phase 3
11 Antiviral Agents Phase 3
12 Immunosuppressive Agents Phase 3
13 Antimetabolites Phase 3
14 Vitamin B Complex Phase 3
15 Folic Acid Antagonists Phase 3
16 Folate Phase 3
17 Vitamin B9 Phase 3
18 Protein Kinase Inhibitors Phase 3
19 Albumin-Bound Paclitaxel Phase 3
20 Tubulin Modulators Phase 3
21 Antimitotic Agents Phase 3
22
Erlotinib Hydrochloride Phase 3 183319-69-9 176871
23
Durvalumab Approved, Investigational Phase 2 1428935-60-7
24
Midazolam Approved, Illicit Phase 1, Phase 2 59467-70-8 4192
25
Tyrosine Approved, Investigational, Nutraceutical Phase 1, Phase 2 60-18-4 6057
26 Mitogens Phase 2
27 Immunoglobulins Phase 2
28 Antibodies Phase 2
29 Antibodies, Monoclonal Phase 2
30 Antineoplastic Agents, Immunological Phase 2
31 Cola Phase 1, Phase 2
32 Technetium Tc 99m Aggregated Albumin Phase 2
33 Radiopharmaceuticals Phase 2
34
Pembrolizumab Approved Phase 1 1374853-91-4
35
Exemestane Approved, Investigational Phase 1 107868-30-4 60198
36
Trametinib Approved Phase 1 871700-17-3 11707110
37
Entinostat Investigational Phase 1 209783-80-2
38
Imidazole Experimental, Investigational Phase 1 288-32-4 795
39 Histone Deacetylase Inhibitors Phase 1
40 Hormones Phase 1
41 Hormone Antagonists Phase 1
42 Estrogen Antagonists Phase 1
43 Estrogen Receptor Antagonists Phase 1
44 Estrogens Phase 1
45 Aromatase Inhibitors Phase 1
46 (R,E)-N-(7-chloro-1-(1-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-1H-benzo(d)... Phase 1
47
Gefitinib Approved, Investigational 184475-35-2 123631
48
Osimertinib Approved 1421373-65-0 71496458
49
afatinib Approved 439081-18-2, 850140-72-6 10184653
50
Cysteine Approved, Nutraceutical 52-90-4 5862

Interventional clinical trials:

(show all 31)
# Name Status NCT ID Phase Drugs
1 A Randomized, Double-blind, Placebo-controlled in Parallel, Multicenter Phase III Trial of Recombinant Human Apo-2 Ligand for Injection(Dulanermin for Injection)in the Treatment of Advanced Non-small Cell Lung Cancer Unknown status NCT03083743 Phase 3
2 Randomized Phase III Multicenter Trial of Customized Chemotherapy Versus Standard of Care for1st Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer Unknown status NCT03402048 Phase 3 Carboplatin;Gemcitabine;Pemetrexed;Docetaxel;Vinorelbine
3 A Phase III, Randomized, Open-Label, Multi-center Study of SHR-1210(Anti-PD-1 Antibody) in Combination With Pemetrexed and Carboplatin as First Line Therapy in Subjects With Advanced/Metastatic Non-squamous Non-small Cell Lung Cancer Completed NCT03134872 Phase 3 Carboplatin;Pemetrexed
4 A Phase III Randomized, Open-Label Clinical Trial of BBI-608 Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer Terminated NCT02826161 Phase 3 Napabucasin;Paclitaxel
5 Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy Terminated NCT02134015 Phase 3 Patritumab;Erlotinib;Placebo
6 A Randomized, Phase II Trial of Icotinib Versus Observation as Adjuvant Treatment in Stage IB Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutation Unknown status NCT02264210 Phase 2 Icotinib
7 A Randomized Phase 2 Trial of Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II, and IIIA Non-small Cell Lung Cancer (NSCLC) Recruiting NCT02904954 Phase 2 Durvalumab
8 A Phase 1b/2, Open-Label, Multicenter Dose-Escalation and Dose-Expansion Study of the Combination of RMC-4630 and Cobimetinib in Adult Participants With Relapsed/Refractory Solid Tumors With Specific Genomic Aberrations Recruiting NCT03989115 Phase 1, Phase 2 RMC-4630;Cobimetinib
9 An Open-label, Single-arm, Multi-center, Phase 2 Study to Evaluate SHR-1210(Anti-PD-1 Antibody) in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Recruiting NCT03085069 Phase 2
10 A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors Recruiting NCT03899792 Phase 1, Phase 2 LOXO-292
11 A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors Recruiting NCT03037385 Phase 1, Phase 2 pralsetinib (BLU-667)
12 A Phase 1/2 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001) Recruiting NCT03157128 Phase 1, Phase 2 LOXO-292 (selpercatinib)
13 A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) Recruiting NCT03093116 Phase 1, Phase 2 Oral repotrectinib (TPX-0005)
14 Thorakoskopische Handheld-SPECT Gesteuerte Ektomie Von Radioaktiv-markierten Pulmonalen Rundherden. Proof of Feasibility of Thoracoscopic Ectomy of Radioactively Marked Pulmonary Nodules With the Help of Free-hand SPECT. Terminated NCT02050724 Phase 2 Radioactive labelling of pulmonary nodules
15 A Phase 1, Randomized, Open-Label, Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors (SNDX-275-0141, MK3475-460/KEYNOTE-460) Unknown status NCT02909452 Phase 1 Entinostat;Pembrolizumab
16 A Phase 1 Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors Completed NCT02897778 Phase 1 Entinostat
17 A Phase I Study to Assess the Food Effect on the Pharmacokinetics of Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic ER+ Breast Cancer and Men and Women With Progressive Non-Small Cell Lung Cancer Completed NCT01594398 Phase 1 entinostat;entinostat;Erlotinib;Erlotinib;Exemestane;Exemestane
18 An Open-label, Multicenter, Phase I Dose-escalation Trial of EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer and Acquired EGFR p.T790M-positive Resistance to 1st or 2nd Generation EGFR TKI Therapy Remark: According to Version V02_0 of the Protocol, Patients May Also be Eligible if EGFR TKI-treatment naïve, EGFR p.T790M-negative at Progression While on EGFR TKI Therapy or After Progression While on Osimertinib Treatment Recruiting NCT03516214 Phase 1 EGF816;Trametinib
19 A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of RMC-4630 Monotherapy in Adult Participants With Relapsed/Refractory Solid Tumors Recruiting NCT03634982 Phase 1 RMC-4630
20 A Multi-centre Observational Study on Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients Under Gefitinib Treatment Unknown status NCT02804100
21 Comparison of Different Types of Surgery in Treating Patients With Early-stage Non-small Cell Lung Cancer Unknown status NCT02288026
22 Cost-consequence Analysis of Parenchymal Stapling Device Versus Hand-sewing for Pulmonary Lobectomy in Lung Disease: A Randomized Controlled Trial Completed NCT01575314
23 Circulating and Local Expression Levels of Survivin and Fibulin-3 in Benign and Malignant Respiratory Diseases Completed NCT04413292
24 Study of the Modification of the Fixation of FDG, F-Miso and FLT Measured in PET/CT at Patients Before and in the Course of Exclusive Radiotherapy or Concomitant Radiochemotherapy for Primitive Bronchial Cancer Completed NCT01261585
25 Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality Completed NCT02378337
26 Assessment of a Novel, Fast and Automatic CT-to-patient Registration Method During Navigated Bronchoscopy and Endobronchial Ultrasound Bronchoscopy (EBUS) Completed NCT02493023
27 Fraxinus- Assessment of an Open Source Virtual Bronchoscopic Navigation System Recruiting NCT03745859
28 Assessment of a Novel, Fast and Automatic CT-to-patient Registration Method During Navigated Bronchoscopy and Endobronchial Ultrasound Bronchoscopy (EBUS) Recruiting NCT02745002
29 trūFreeze® Spray Cryotherapy Patient Registry Active, not recruiting NCT01802203
30 CSP #2005 - Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy Trial (VALOR) Active, not recruiting NCT02984761
31 Global PANORAMA Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes in Patients With Locally Advanced or Metastatic NSCLC. Terminated NCT03053297

Search NIH Clinical Center for Bronchial Benign Neoplasm

Cochrane evidence based reviews: bronchial neoplasms

Genetic Tests for Bronchial Benign Neoplasm

Anatomical Context for Bronchial Benign Neoplasm

MalaCards organs/tissues related to Bronchial Benign Neoplasm:

40
Lung, Thyroid, Breast, Testes

Publications for Bronchial Benign Neoplasm

Articles related to Bronchial Benign Neoplasm:

# Title Authors PMID Year
1
[Hospital undertaking of patients with a resection of lung cancer]. 61
24034457 2013

Variations for Bronchial Benign Neoplasm

Expression for Bronchial Benign Neoplasm

Search GEO for disease gene expression data for Bronchial Benign Neoplasm.

Pathways for Bronchial Benign Neoplasm

GO Terms for Bronchial Benign Neoplasm

Sources for Bronchial Benign Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....